CloneID: MV129
Antigen Long Description: The original antibody was isolated from PBMCs of human patients using high-throughput single-cell RNA and V(D)J sequencing of antigen-sorted B cells from patients with convalescent monkeypox.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: Q80KX2
Specificity Statement: This antibody binds the A35 protein of the monkeypox virus and also cross reacts with A33R protein of vaccinia virus. Mpox is an infectious disease caused by the monkeypox virus which can be transmitted to humans through physical contact with someone who is infectious, with contaminated materials, or with infected animals. It can cause a painful rash or mucosal lesions which can last 2–4 weeks, enlarged lymph nodes and fever. Monkeypox mortality rates range from 0%-11% in the general population and are higher in young children. In Q3 of 2024, the WHO declared monkeypox
a Public Health Emergency of International Concern. This product serves as a powerful tool for related research efforts.
Application Notes (Clone): This antibody strongly reacted with MPXV A35 protein in an ELISA assay at half-maximal effective concentrations (EC50) of 0.035 μg/mL. The binding affinity of the original human IgG1 version for MPXV A35 protein was determined using BLI and was reported to be Kd = 2.19 pM. In an in vitro virus neutralization assay, this antibody exhibited a strong neutralizing activity, with an IC50 of 2.68 μg/mL. This antibody was capable of recognizing MPXV A35 protein from convalescent serum samples in a western blot (PMID: 39002567).
Deutsch
English
